| Revenue | NOK 0 | — |
| EBITDA | NOK -202K | +52% |
| Net profit | NOK -202K | +52% |
| Total assets | NOK 1,2M | +68% |
| Equity | NOK 1,1M | +20290% |
| Employees | 4 | — |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 120 | 0 | 280 | 0 |
| Staff expenses | −0 | −0 | −216 | −0 |
| EBITDA | −4 | −158 | −424 | −202 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −4 | −158 | −424 | −202 |
| Net financials | −0 | −2 | −2 | −1 |
| Profit before tax | −4 | −160 | −425 | −202 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −4 | −160 | −425 | −202 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 700 | 641 | 701 | 1 181 |
| Equity | 590 | 431 | 5 | 1 093 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 110 | 211 | 696 | 89 |
| Total debt | 110 | 211 | 696 | 89 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DH Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Medcis As | Company | 33.3% | 33.3% | 2024 |
Lumar As | Company | 33.3% | 33.3% | 2024 |
Ombio As | Company | 28.3% | 28.3% | 2024 |
Norprocess As | Company | 5.0% | 5.0% | 2024 |
| Person | Role here | Other companies |
|---|---|---|
| Dag Hjelle | Chief Executive Officer | 0 companies |
| Olaf Brage Marvik | Board of Directors | 0 companies |
| Gunnar Sæthern Eskeland | Board of Directors | 0 companies |
| Øystein Selen | Board of Directors | 0 companies |
| Ole Jørgen Marvik | Board of Directors | 0 companies |
| Olav Asle Djupevåg | Board of Directors | 0 companies |